New Products Posted to GenomeWeb: Active Motif, GC Genome/Celemics, Codex, More

Active Motif Recombinant COVID-19 Antibodies

Active Motif said that in February it successfully isolated antibodies from patients in China recovering from COVID-19, and that the full suite of antibodies is now available for research applications and diagnostic test development. In collaboration with Fudan University and its Public Health Clinical Center, the company used its proprietary single-cell AbEpic screening technology to isolate the antibodies from patients, whose samples were screened to obtain whole human IgG antibody clones that have been sequenced, expressed, and characterized for binding directly to the SARS-CoV-2 S1 protein.

GC Genome/Celemics: SARS-CoV-2 BTSeq Sequencing Service

Korean firms GC Genome and Celemics have launched a SARS-CoV-2 sequencing service. As part of the service, GC Genome will use Celemics' Barcode-Tagged Sequencing (BTSeq) technology, which can analyze sequence sizes of less than 1 kb to a maximum of 30 kb with an error rate of less than .001 percent per base pair, the companies said. This enables analysis of both PCR products and full SARS-CoV-2 genomes. Turnaround time is usually less than 10 days but can be minimized to one day, the companies said. The partners said that the service can reveal information on the epidemiology and pathogenesis of the virus and enable mutant surveillance.

Codex Synthetic DNA Products for COVID-19 Research

Codex has launched a number of newly developed products and services for COVID-19 research and diagnostic/vaccine development. The new products include:

• SARS-CoV-2 diagnostic RNA controls: safe positive controls that replace the need for live virus in RT-PCR and NGS testing protocols
• SARS-CoV-2 antigen panels and antibody libraries: allow for rapid design and iteration of antigens or antibody libraries for the development of vaccines and therapeutics using the company's BioXp 3200 gene automated synthesis platform.
• SARS-CoV-2 spike protein DNA vaccine construct, mRNA vaccine scaffold, and live attenuated vaccine scaffold for vaccine development
• SARS-CoV-2 synthetic DNA parts: span the whole genome and useful for developing DNA, RNA, and viral vector vaccines and pan-genome diagnostics
• SARS-CoV-2 full-length synthetic genome: the Wuhan-Hu-1 strain of SARS-CoV-2 cloned in a bacterial artificial chromosome for the development of vaccines, therapeutics, and diagnostics.